本次合作有利于进一步加快许可产品在全球范围的临床开发和商业化进程，并持续拓展本集团创新产品 的海外布局。 复星医药（600196）(600196.SH)发布公告，2025年8月11日，公司控股子公司复星医药产业与 Expedition签订《许可协议》，复星医药产业授予Expedition除中国境内及港澳地区以外的全球范围、许 可领域内开发、生产及商业化在研产品XH-S004的权利。本次合作后，集团仍拥有许可产品于中国境内 及港澳地区的开发、生产及商业化权利。 XH-S004为集团拥有自主知识产权的小分子口服DPP-1抑制剂，其通过抑制DPP-1及其激活的中性粒细 胞丝氨酸蛋白酶降低炎症反应，从而阻断感染恶性循环及由此导致的气道结构损伤。该在研药品的潜在 适应症包括非囊性纤维化支气管扩张症、慢性阻塞性肺疾病等。根据约定，Expedition将就本次合作向 复星医药产业支付至多1.2亿美元不可退还的首付款、开发及监管里程碑付款，此外，基于许可产品于 许可区域的年度净销售额达成情况，由Expedition向复星医药产业依约支付至多5.25亿美元的销售里程 碑款项。 ...

Group 1 - The company held its 15th meeting of the 10th board of directors on May 30, 2025, with all 9 directors participating, complying with relevant laws and regulations [1] - The company plans to hold the 2024 annual shareholders' meeting on June 20, 2025, with all votes in favor [1] - The board approved amendments to the "Performance Bonus Incentive Measures" to optimize the incentive mechanism and enhance overall operational efficiency [2] Group 2 - The company’s wholly-owned subsidiary, Harbin Pharmaceutical Group Bioengineering Co., Ltd., signed a technology transfer contract with Shanghai Bozhi Research New Drug Co., Ltd., with a total contract value of 44.8 million yuan [2] - The contract includes clear terms regarding technical objectives, payment methods, and liability for breach of contract, acknowledging the uncertainties involved in drug development [3] - The company will adhere to information disclosure obligations as per the Shanghai Stock Exchange regulations [3]